Dutch competition authority ACM imposes EUR 20 million fine on orphan drug manufacturer Leadiant for excessive pricing* The Netherlands Authority for the Consumer and Markets’ (“ACM“) announced focus on drug price developments has finally come to a tangible enforcement result: a fine of almost EUR 20 million imposed on Leadiant, manufacturer of the orphan drug CDCA-Leadiant. This penalty decision follows the announcement by the ACM in 2018, repeated in 2020 and 2021, that it would scrutinize the over-pricing of medicines. The prices of medicines have long been part of a public debate. In its role of the Dutch competition authority, the ACM got involved in that debate, but so far its participation had been limited to academic-scientific discussions (see for example here and here). This
Share on
|
|
The Dutch Competition Authority imposes a fine totalling €20M on an orphan drug manufacturer for excessive pricing (Leadiant)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
